Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer  Elaine Y.L. Leung, MB ChB,

Published bySelma Paulsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer  Elaine Y.L. Leung, MB ChB,"— Presentation transcript:

1 Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer  Elaine Y.L. Leung, MB ChB, Hazel R. Scott, MD, Donald C. McMillan, PhD  Journal of Thoracic Oncology  Volume 7, Issue 4, Pages (April 2012) DOI: /JTO.0b013e318244ffe1 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 A, The relationship between the modified Glasgow prognostic score (mGPS; 0, 1, 2 from top to bottom) and cancer-specific survival in patients with inoperable non-small cell lung cancer (p < ). B, The relationship between tumor, node, metastasis (TNM) stage (III, IV from top to bottom) and cancer-specific survival in patients with inoperable non-small cell lung cancer (p = 0.001). C, The relationship between Eastern Cooperative Oncology Group performance status (ECOG-PS) (PS = 0 to 3 from top to bottom) and cancer-specific survival in patients with inoperable non-small cell lung cancer (p < 0.001). D, The relationship between treatment received (palliation only to chemoradiation from top to bottom) and cancer-specific survival in patients with inoperable non-small cell lung cancer (p < ). Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318244ffe1) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 A, The relationships between modified Glasgow prognostic score (mGPS) and cancer-specific survival in patients with inoperable non-small cell lung cancer and Eastern Cooperative Oncology Group performance status (ECOG-PS) = 0 or 1 (p = 0.042). B, The relationships between mGPS and cancer-specific survival in patients with inoperable non-small cell lung cancer and ECOG-PS = 2 or 3 (p = 0.009). Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318244ffe1) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 A, The relationships between modified Glasgow prognostic score (mGPS) and cancer-specific survival in patients with inoperable non-small cell lung cancer and received palliative treatment (n = 165; p < ). B, The relationships between mGPS and cancer-specific survival in patients with inoperable non-small cell lung cancer and who received active treatment (n = 96; p = 0.142). Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318244ffe1) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer  Elaine Y.L. Leung, MB ChB,"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
PUBLISH ONLY Journal of Thoracic Oncology

PUBLISH ONLY Journal of Thoracic Oncology
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.
Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma  Clive J. Kelty, MB, ChB, PhD, FRCSEd,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status  Young Joo Lee, MD, Heung Tae Kim, MD,
Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Similar presentations

Ads by Google